Searched for
GENERICS BUSINESS
As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent PharmaceuticalsTorrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...- ChrysCapital acquires controlling 70.68% stake in Novartis India listed unit in first majority pharma investmentChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- NPCIL invites bids for engineering, 3D design of Bharat Small ReactorsThe Nuclear Power Corporation of India Ltd is on the lookout for expert consultants to assist with both plant engineering and 3D modelling ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Private equity investors shift tech bets from IT services to AI startupsBankers and investors told ET that interest is expanding beyond capital-intensive AI infrastructure to applications that automate business ...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- SAP CFO says AI must move beyond chatbot 'low-hanging fruit' before seeing returnsCompanies have poured money into generative AI but are still seeking evidence of broad productivity gains, and SAP is arguing that the re...
- Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPCMarkets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...
- Cipla expects sequential recovery in North America on new product launches despite tariff uncertaintyCipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...
- Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practicalUS President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...
- Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target pricesDr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...
- Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...
- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn SaldanhaGlenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from...
- The AI race isn't about bigger models—it's about IndiaIndia can become the world's AI deployment hub by leveraging its software engineering workforce and enterprise IT experience. Enterprises w...
- Why the future of enterprise AI depends on better decisions, not bigger modelsEnterprise AI success hinges on enabling better business decisions. Larger AI models do not guarantee improved operational efficiency or co...
Load More
